Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis

NCT04660747

Status	RECRUITING
Sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Enrollment	1,300 participants

Key Eligibility Criteria

Inclusion (5)

- Written informed consent for the use of observational data
- Age \>18 years at the time of CVT diagnosis
- Radiologically confirmed CVT diagnosis (CT-venography, MRI or catheter angiography)
- Oral anticoagulant treatment (DOAC or VKA) started within 30 days of CVT diagnosis (patient may initially be treated with heparin)
- Inclusion in the study within 90 days of CVT diagnosis

Exclusion (5)

- Anticoagulant treatment at the time of CVT diagnosis
- Pregnancy or lactation (post-partum women are eligible if they do not give breast-feeding)
- Mechanical heart valve
- Severe renal insufficiency (defined as an eGFR \<15 ml/min)
- Severe liver disease resulting in clinically relevant coagulopathy

Locations (1 total)

Jonathan Coutinho, Amsterdam, North Holland, Netherlands